Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
N NERVOUS SYSTEM
N02 ANALGESICS
N02C ANTIMIGRAINE PREPARATIONS
N02CD Calcitonin gene-related peptide (CGRP) antagonists
N02CD06 Rimegepant
D10663 Rimegepant sulfate (USAN) <US>
USP drug classification [BR:br08302]
Antimigraine Agents
Calcitonin Gene-Related Peptide (CGRP) Receptor Antagonist
Rimegepant
D10663 Rimegepant sulfate (USAN)
Therapeutic category of drugs in Japan [BR:br08301]
1 Agents affecting nervous system and sensory organs
11 Agents affecting central nervous system
119 Miscellaneous
1190 Miscellaneous
D10663 Rimegepant sulfate (USAN); Rimegepant sulfate hydrate (JAN)
Drug groups [BR:br08330]
Metabolizing enzyme substrate
DG01642 CYP2C9 substrate
DG01845 Rimegepant
D10663 Rimegepant sulfate
DG01633 CYP3A/CYP3A4 substrate
DG02913 CYP3A4 substrate
DG01845 Rimegepant
D10663 Rimegepant sulfate
Target-based classification of drugs [BR:br08310]
G Protein-coupled receptors
Secretin receptor family
Calcitonin
CALCRL
D10663 Rimegepant sulfate (USAN) <JP/US>
New drug approvals in the USA [br08319.html]
New molecular entities and new therapeutic biological products
D10663
New drug approvals in Europe [br08329.html]
European public assessment reports (EPAR) authorised medicine
D10663
New drug approvals in Japan [br08318.html]
Drugs with new active ingredients
D10663
New drug approvals in the USA, Europe and Japan [br08328.html]
Approval dates by FDA, EMA and PMDA
D10663
Drug metabolizing enzymes and transporters [br08309.html]
Drug metabolizing enzymes
D10663
Drug groups [BR:br08330]
Metabolizing enzyme substrate
DG01642 CYP2C9 substrate
DG01845 Rimegepant
DG01633 CYP3A/CYP3A4 substrate
DG02913 CYP3A4 substrate
DG01845 Rimegepant